We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Ligation Is Viable Option to Vasectomy

By HospiMedica staff writers
Posted on 02 Jun 2006
A new study reports that ligation of the vas deferens with a biocompatible clip appears to be as effective as vasectomy in achieving male sterility. More...


The Vasclip implant device, marketed by VMBC (White Bear Lake, Minnesota, USA), is a small, hinged, biocompatible, implantable polymeric lock that stays in place after the physician applies one to each vas deferens. About the size of a grain of rice, the implant procedure can be performed under local anesthesia in an office-based setting. The Vasclip procedure averages less than 10 minutes, compared with 30 to 45 minutes for a typical vasectomy. The device has been cleared by the U.S. Food and Drug Administration (FDA).

A study by Dr. Patrick J. Parks and colleagues from Histopathometrics (Mendota Heights, MN, USA) examined 124 men who were eligible for vasectomy but selected ligation instead. On the basis of azoospermia at 10 to 14 months, the procedure was deemed successful in 116 of 119 patients. The three patients who did not achieve sterility were later found to have misaligned Vasclips, which led to a partial incision of the vas, allowing recanalization. The results were published in the April 2006 issue of Urology.

The Vasclip works by atraumatically closing the vas deferens on itself without cutting the vessel, thus stopping the flow of sperm. Because the physician does not need to cut or cauterize the vas deferens, complications such as swelling and infection are reduced. As with a vasectomy, the procedure should be considered permanent. Patients must continue to use other forms of birth control and have semen analysis tests performed until they are advised by their physician that they are infertile.



Related Links:
VMBC

Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Endoscopy Display
E190
ow Frequency Pulse Massager
ET10 L
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The researchers grew pancreatic tissue (above) so it incorporated a mesh-like electronic network (red). Cells within the tissue produce insulin (green). (Photo courtesy of Penn Medicine)

‘Cyborg’ Transplants Could Replace Pancreatic Tissue Damaged by Diabetes

Type 1 diabetes destroys insulin-producing islet cells, forcing patients to rely on lifelong insulin therapy or scarce organ transplants. Although lab-grown pancreatic tissue offers a promising alternative,... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.